HollyHerman.com Editorial Team | Published April 17, 2026
Disclaimer: These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is medical advice. I'm not a doctor, registered dietitian, or licensed healthcare provider. Everything here is based on personal research and testing experience. If you have a health condition or take prescription medications, consult your physician before making any changes. Some links in this article may be affiliate links — this is disclosed on the affiliate disclosure page.
If you've read through the GLP-1 explainer and the access guide, you're at the decision point: which program to actually use. This article is for that step — evaluating what's out there, what the differences actually are, and how to match the options to your specific situation.
Let me be upfront about what this article is and isn't. It's a framework for evaluating programs, not a simple “here's the best one” answer, because the best one genuinely depends on what you're optimizing for. Cost, physician oversight quality, medication type, ongoing support — these matter differently depending on your situation. What I can do is give you the criteria that separate programs worth considering from ones that aren't, and walk through how those criteria apply.
The Five Criteria That Actually Matter
There are a lot of telehealth GLP-1 programs out there now. Most of them look similar on a landing page. The differences that actually matter are mostly invisible until you're already in the process — which is why it's worth knowing what to look for before you start.
1. Quality of physician oversight. Is there a real, substantive medical review of your health history before a prescription is issued? The minimum standard: a licensed physician or nurse practitioner actually reads your intake, evaluates your history for contraindications, and makes a clinical judgment. The flag to avoid: platforms where approval happens within minutes of submitting intake, suggesting an automated process rather than actual review. GLP-1 medications have specific contraindications and require clinical judgment to prescribe safely — the physician review step is not bureaucracy.
2. Pharmacy transparency. Compounded semaglutide and tirzepatide are prepared at compounding pharmacies. A legitimate program should be able to tell you specifically which pharmacy prepares your medication, confirm that it holds 503A or 503B status, and provide labeling showing the active ingredient and dose. If you can't get a direct answer to “which pharmacy makes my medication and can you confirm their regulatory status,” that's a meaningful red flag. The compounded semaglutide safety article covers how to verify this independently.
3. Titration protocol included. Your prescription should come with a dose escalation schedule — a plan for starting at a low dose and gradually increasing over weeks. The gastrointestinal side effects of GLP-1 medications are primarily a dose escalation problem; they're most manageable when dose increases are gradual. A provider who prescribes without a titration protocol is providing incomplete care. Confirm that the titration schedule is included before you start.
4. Ongoing provider access. What happens when you have questions, side effects, or need to adjust your dose? Can you reach someone? Is there a messaging system with actual response times? Ongoing provider access is a meaningful differentiator — not because most people use it constantly, but because the times you need it (nausea management, dose questions, unexpected effects) matter and deserve prompt response.
5. Clear cancellation and refund terms. Some programs offer refunds if a prescription isn't issued. Others have cancellation windows, subscription models, or terms that make stopping difficult. Understanding the financial commitment and exit terms before you start is worth the two minutes it takes to find them. Look for the terms on the program website before providing payment information.
Semaglutide vs. Tirzepatide: How to Think About the Choice
The two medication classes that dominate the telehealth GLP-1 market are semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). The clinical trial data is clear that tirzepatide produced stronger average weight loss — approximately 20.9% versus 14.9% in respective trials. What that difference means in the decision:
Semaglutide has a longer track record. Semaglutide has been in clinical use longer, has more long-term safety data, and is the established standard for GLP-1 weight management treatment. For someone starting for the first time, it's a lower-uncertainty choice.
Tirzepatide's stronger trial results are meaningful — but individual variation is high. The ~6% average trial difference doesn't guarantee a 6% better outcome for any specific individual. Some people respond better to semaglutide; the mechanisms of GLP-1 and GIP combined don't work identically for everyone.
Cost matters. Compounded tirzepatide typically runs $100 to $200 per month more than compounded semaglutide. That's $1,200 to $2,400 per year. For some people, starting with semaglutide and evaluating response before deciding whether to switch makes more financial sense than committing to tirzepatide immediately.
For the injection-averse: oral GLP-1 options now exist. Orforglipron (the active compound in Foundayo and other brand names), which received FDA approval in 2026, is a fully oral daily pill. It showed approximately 9–10% weight loss in trials — lower than injectables, but removal of the injection barrier makes it the right choice for a meaningful segment of people for whom injectables are a dealbreaker. If needles are the reason you haven't considered this class at all, oral options are worth knowing about.
Decision Framework: Matching Your Situation to the Right Starting Point
If your primary constraint is cost: Compounded semaglutide at starter dose, from a platform with transparent pharmacy information and physician oversight. This is the lowest-cost entry point with adequate clinical support. Verify the pharmacy, confirm the titration protocol, and start there. Upgrade later if needed.
If you want the strongest clinical evidence and don't want to think about it: A platform offering brand-name Wegovy or Zepbound with manufacturer savings programs. Higher cost but FDA-approved finished products with the full manufacturer quality and safety documentation. Insurance verification support from the platform is worth seeking out.
If you want the best possible weight loss outcomes and cost is secondary: Tirzepatide (compounded or brand-name Zepbound) with robust physician oversight and ongoing support. The trial data points to tirzepatide for people for whom maximizing outcome is the primary variable.
If injections are a dealbreaker: Oral GLP-1 programs featuring orforglipron or oral semaglutide (Wegovy pill, where available). Expect more modest outcomes than injectables but a fully needle-free experience.
If you have complex medical history: In-person physician or specialist care, not telehealth. Telehealth platforms are appropriate for medically straightforward cases. If you take multiple medications with potential interactions, have cardiovascular history, or have conditions requiring ongoing monitoring, in-person specialist oversight is the appropriate route regardless of convenience or cost considerations.
When None of These Is the Right Answer
There are situations where GLP-1 telehealth — or GLP-1 medications entirely — is not the right fit. These include: not meeting BMI criteria (under 27, without weight-related conditions); the specific contraindications discussed in the GLP-1 explainer; and situations where the primary driver of weight difficulty is a separately diagnosable condition (thyroid, PCOS, insulin resistance requiring specialist management) that should be addressed directly first.
There is also a timing question worth considering honestly. GLP-1 medications work best when sleep, protein intake, and some baseline physical activity are in place — not because those things are requirements for eligibility, but because the mechanisms complement each other and the outcome is better when the behavioral foundation exists. If sleep quality or stress is severely dysregulated, addressing those before or alongside starting a GLP-1 program is worth doing.
Timeline Expectations Worth Setting Now
So you start a program. What happens and when?
Weeks 1–2: Dose titration begins. Nausea is most common in this phase. Many people notice reduced appetite within the first week or two — the GLP-1 signal doesn't take long to produce appetite changes.
Weeks 4–8: Meaningful weight loss typically begins appearing in this window. The satiety effect is established; eating naturally decreases. This is when most people report the qualitative shift — the relationship with hunger feels different.
Months 3–6: The strongest rate of weight loss for most people. Still on dose escalation for many; the appetite suppression is well-established.
Month 12+: Rate of loss slows toward a plateau at the maintained dose. Average clinical trial outcomes are measured at 68–72 weeks. This is a long-term treatment, not a 30-day program. The medication works while you take it — the question of how long to continue is one for your prescribing physician.
What the 2026 Compounding Crackdown Means for Your Decision
In February 2026, FDA Commissioner Marty Makary announced the agency's intent to crack down on compounded GLP-1 medications. This followed the FDA's removal of semaglutide from its official drug shortage list — the shortage status had provided the legal basis under which 503A and 503B pharmacies were compounding semaglutide at scale. With semaglutide off the shortage list, the enforcement discretion that had effectively allowed widespread compounded semaglutide to flow through telehealth platforms no longer applies in the same way.
What this means practically: the compounded semaglutide market is under active regulatory pressure. Some telehealth platforms are pivoting toward compounded tirzepatide (which has a different regulatory status), toward brand-name medications with manufacturer savings programs, or toward newer oral options like Foundayo (orforglipron) that are FDA-approved as finished products and thus not subject to the same compounding restrictions. If you're comparing telehealth programs specifically for compounded semaglutide, the regulatory situation as of April 2026 is actively evolving, and any platform you choose should be able to articulate how they're navigating the current FDA guidance. Platforms that can't answer this question clearly are operating without the visibility you need.
For the injection-averse or anyone who wants a medication not caught in the compounding regulatory debate: Foundayo (orforglipron) is a fully oral, FDA-approved daily pill — not compounded, not injectable, and not subject to the shortage/compounding framework. It showed approximately 9–11% weight loss in phase 3 trials, which is lower than injectable semaglutide or tirzepatide, but it's an FDA-approved finished product, taken daily like any other pill, available through standard prescription. For a subset of people, removing the needle and the compounding complexity entirely is worth the outcome tradeoff.
Frequently Asked Questions
What Should I Look for in a GLP-1 Telehealth Program?
Five things: substantive physician review (not automated approval); named, verified compounding pharmacy with 503A or 503B status; included titration protocol with your prescription; ongoing provider access for questions and side effects; and clear cancellation and refund terms before you commit financially. Programs that are strong on all five are meaningfully differentiated from programs that aren't.
How Do I Choose Between Semaglutide and Tirzepatide?
Tirzepatide showed stronger average trial outcomes (approximately 20.9% vs 14.9%). Semaglutide has a longer track record and established long-term safety data. Tirzepatide typically costs more. For most people starting for the first time, semaglutide is a reasonable first choice with the option to switch if results are inadequate. The conversation is most productively had with the prescribing physician who knows your history.
Is Compounded GLP-1 as Effective as Brand Name?
Compounded semaglutide contains the same active ingredient at comparable doses. There are no head-to-head trials comparing compounded to brand-name. What matters most is pharmacy quality — a properly licensed and regulated compounding pharmacy producing a product with verified active ingredient and dosing. The safety article on this site covers how to evaluate this.
The statements on this page have not been evaluated by the Food and Drug Administration. Nothing on HollyHerman.com constitutes medical advice. Holly Herman is not a licensed healthcare provider. Individual circumstances vary. Consult your physician before starting, stopping, or changing any medication or health approach.
Leave a Reply
You must be logged in to post a comment.